Daclatasvir

Paul G. Auwaerter, M.D., Janessa M. Smith, PharmD, BCPS

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
    • Daclatasvir is indicated for treating HIV/HCV co-infected patients in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis, and in patients that develop recurrent HCV post-transplant.

NON-FDA APPROVED USES

Treatment of HCV genotypes 2, 4.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 18, 2022